Because of the rapid proliferation of tumor cells and increased demand for iron, TfR has been proven to be overexpressed in various kinds of tumor cells, including brain, liver, and lung cancers, whereas it is low-expressed in normal cells [7,8], which makes it an excellent target for tumor-targeted drug delivery systems (DDSs). The gene discussed is TFRC; the disease is neoplasm.